Considering the established evidence on CV benefit, GLP-1 RA and SGLT2i should be considered to be the first choice in patients with T2D at high CV risk, alone or in combination with metformin or each other [158]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.